How does CMRT work?

CMRT focuses on the premise that most harmful pharmacological or toxic encounters in the body will also form a parallel immune system challenge. The immune system recognizes the presence of a foreign substance, identifies its nature and then mounts a defensive action against it. Part of that defensive action is the production of specific antibodies which contribute to neutralizing the targeted foreign substance, destroying or altering its structure and binding the substance preparatory to its removal from the encounter site and elimination from the system.

Even after the offending foreign substance can no longer be detected in body fluids and tissues, the specific antibodies against it remain present in the plasma/serum of the blood for a period of months to years. Additional quantities of the specific antibody can be quickly produced in the future if needed due to certain memory lymphatic cells which have a long-term, enduring record of the antibody which counters the foreign substance. These memory cells will facilitate a quick response with replenishment of antibodies in the blood as needed.

Sadly, the immune system is not especially effective in protecting the patient when it comes to the foreign substances such as those associated with restorative and reconstruction biomaterials. However, the requisite antibody response still takes place and the antibodies remain for extended periods of time. Detecting those antibodies at or above a relevant clinical threshold level is a useful indicator that the patient has experienced an adverse encounter with the offending substance and has developed a systemic sensitivity to it.

CMRT looks for the presence of antibodies in patient serum at or above a relevant threshold which have been formed against the chemical groups and families of compounds that can be released from restorative and reconstruction biomaterials. The contributing source which initiated the creation of the antibodies is somewhat immaterial. Whether the offending substance first came from prior placement of the substance as part of a medical or dental procedure, or whether it came from food, water or environmental contact sources, once the body becomes sensitized it will react with the substance from any future source.

Thus, if the patient has become sensitized to the offending substance from any source whatsoever, the dentist or physician will want to avoid placing new biomaterials which can exacerbate that existing sensitivity. CMRT identifies the reactive chemical group or family, and then correlates that finding with our database of biomaterials by trade-name. At the same time, it also indicates all products in the database by trade-name which have not shown any contraindicating components. The healthcare professional can easily check available biomaterials and identify those to avoid for the patient.